{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:06:59Z","timestamp":1790208419532,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>In the Department of Parasitology and Mycology of Toulouse University Hospitals, patients presenting with common\/covert toxocariasis were treated either with albendazole (39 cases) or with diethylcarbamazine (32 cases). Albendazole (ABZ) was given at 10 mg\/kg b\/w daily for 14 days, and diethylcarbamazine (DEC) was given at 4 mg\/kg b\/w daily for 21 days. In both groups, follow-up consultations occurred approximately 48 days after the end of the anthelmintic therapy. ABZ and DEC displayed a similar efficacy on the kinetics of the clinical picture (\u221264.5% of reduction vs. \u221272.7%, respectively) and on the levels of blood eosinophilia, serum eosinophil cationic protein and serum total IgE. However, the effect of the medication on the laboratory parameters was moderate. The rate of adverse reactions was similar in both groups (38% for ABZ vs. 31% for DEC), but DEC-treated patients complained of more intense and long-lasting side effects. The DEC group had more major adverse reactions, resulting in the termination of the anthelmintic treatment. The results from this retrospective study bring further arguments for considering ABZ, given at 10 mg\/kg daily for 2 weeks, as the drug of choice in the treatment of human toxocariasis.<\/jats:p>","DOI":"10.3390\/pathogens11070813","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T03:34:40Z","timestamp":1658374480000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Retrospective Study of the Efficacy of Albendazole and Diethylcarbamazine for the Treatment of Human Toxocariasis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7759-894X","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Magnaval","sequence":"first","affiliation":[{"name":"Service de Parasitologie M\u00e9dicale, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Toulouse III, 37 all\u00e9es Jules-Guesde, 31000 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-189X","authenticated-orcid":false,"given":"Judith","family":"Fillaux","sequence":"additional","affiliation":[{"name":"Service de Parasitologie-Mycologie, H\u00f4pital Purpan, Centre Hospitalier Universitaire de Toulouse, 330 avenue de Grande-Bretagne, 31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Berry","sequence":"additional","affiliation":[{"name":"Service de Parasitologie-Mycologie, H\u00f4pital Purpan, Centre Hospitalier Universitaire de Toulouse, 330 avenue de Grande-Bretagne, 31059 Toulouse, France"},{"name":"UMR Infinity, Institut Toulousain des Maladies Infectieuses et Inflammatoires, Inserm-CNRS-Universit\u00e9 de Toulouse III, 31024 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bruschi, F. (2014). Toxocariasis. Helminth Infections and their Impact on Global Public Health, Springer.","DOI":"10.1007\/978-3-7091-1782-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/oxfordjournals.epirev.a036235","article-title":"Epidemiology and pathogenesis of zoonotic toxocariasis","volume":"3","author":"Glickman","year":"1981","journal-title":"Epidemiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104002","DOI":"10.1016\/j.meegid.2019.104002","article-title":"Human toxocariasis\u2014A look at a neglected disease through an epidemiological \u2018prism\u2019","volume":"74","author":"Rostami","year":"2019","journal-title":"Infect. Genet. Evol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S1473-3099(17)30331-6","article-title":"Human toxocariasis","volume":"18","author":"Ma","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00034983.1989.11812374","article-title":"Thiabendazole vs. albendazole in treatment of toxocariasis: A clinical trial","volume":"83","author":"Schubarth","year":"1989","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Magnaval, J.F., Bouhsira, E., and Fillaux, J. (2022). Therapy and prevention for human toxocariasis. Microorganisms, 10.","DOI":"10.3390\/microorganisms10020241"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/oxfordjournals.aje.a114618","article-title":"Visceral larva migrans in French adults: A new disease syndrome?","volume":"125","author":"Glickman","year":"1987","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","first-page":"15","article-title":"A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia","volume":"4","author":"Magnaval","year":"2017","journal-title":"Mil. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vetpar.2012.12.028","article-title":"Laboratory diagnosis of human toxocariasis","volume":"193","author":"Fillaux","year":"2013","journal-title":"Vet. Parasitol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0031182000065240","article-title":"Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis","volume":"110","author":"Magnaval","year":"1995","journal-title":"Parasitology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","article-title":"Placebo response and effect in randomized clinical trials: Meta-research with focus on contextual effects","volume":"22","author":"Juhl","year":"2021","journal-title":"Trials"},{"key":"ref_12","unstructured":"Lewis, J.W., and Maizels, R.M. (1993). Antibody reactivity in human toxocariasis. Toxocara and Toxocariasis: Clinical, Epidemiological and Molecular Perspectives, The British Society for Parasitology with the Institute of Biology."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(95)90202-3","article-title":"Chronic urticaria and Toxocara canis","volume":"345","author":"Wolfrom","year":"1995","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000018493","article-title":"Skin manifestations associated with toxocariasis: A case-control study","volume":"201","author":"Humbert","year":"2000","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1346-8138.2003.tb00477.x","article-title":"Tissue parasites in patients with chronic urticaria","volume":"30","author":"Demirci","year":"2003","journal-title":"J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12361","DOI":"10.1097\/MD.0000000000012361","article-title":"Clinical course and treatment outcomes of toxocariasis-related eosinophilic disorder","volume":"97","author":"Yoon","year":"2018","journal-title":"Medicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000234749","article-title":"Eosinophils and human disease","volume":"88","author":"Gleich","year":"1989","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.inf.0000217415.68892.0c","article-title":"Mazzotti reaction after presumptive treatment for schistosomiasis and strongyloidiasis in a Liberian refugee","volume":"25","author":"Olson","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/01.inf.0000243915.52356.44","article-title":"Mazzotti-like reaction after treatment with praziquantel for schistosomiasis","volume":"25","author":"Shorter","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(59)90612-9","article-title":"Tropical eosinophilia experiments with toxocara canis","volume":"2","author":"Chaudhuri","year":"1959","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14787210.7.2.145","article-title":"Benzimidazoles for the treatment of cystic and alveolar echinococcosis: What is the consensus?","volume":"7","author":"Vuitton","year":"2009","journal-title":"Expert Rev. Anti Infect. Ther."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/7\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:54:45Z","timestamp":1760140485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/7\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["pathogens11070813"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11070813","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}